InvestorNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Sale of Proprietary MiQLab System to Denver Animal Emergency

June 7, 2021 09:04:57
LexaGene (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has received a purchase order for its exclusive MiQLab System(TM) from Denver Animal Emergency. The North Carolina emergency medicine and compassionate care facility has been using LexaGene’s MiQLab for several months. In placing the order, the organization noted that that it had compared the accuracy of the MiQLab to results generated by culture and had seen such high concordance that the facility is running MiQLab more often than it is sending samples out for culture. The organization noted that the system identifies not just the most common pathogens but also many common antimicrobial resistance factors, which boosts the confidence of its veterinarians that their prescribed therapies will effectively treat the infection. “I’m pleased that Dr. Pierce and his team at Denver Animal Emergency has decided to purchase the MiQLab System,” said LexaGene founder and CEO Dr. Jack Regan in the press release. “Dr. Pierce is sending a strong message to his patients that the benefits of point-of-care diagnostics, time to result and high concordance will lead to improved animal care and better medical outcomes for our companion animals. This is exactly why LexaGene is in veterinary health and why we aim to change the way veterinary diagnostics are done. No longer is it necessary to wait days for culture when you can have such a powerful point of care diagnostic tool like the MiQLab. . . . I’m excited to report that our newly hired veterinary sales representatives are pursuing many promising leads throughout their territories. Their enthusiasm continues to grow as veterinarians are expressing their desire for in-hospital diagnostics. We look forward to announcing more veterinary sales soon.” To view the full press release, visit https://ibn.fm/7nDbQ About LexaGene Holdings Inc.  LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. LexaGene’s MiQLab(TM) system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com. NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.